Delivers First-Quarter Net Revenues of $13.343 Billion, an Increase of 8.4 Percent on a Reported Basis or 9.8 Percent on an Operational Basis "AbbVie's first-quarter results were well ahead of our ...

NORTH CHICAGO, Ill. (AP) — NORTH CHICAGO, Ill. (AP) — AbbVie Inc. (ABBV) on Friday reported first-quarter profit of $1.29 billion. The North Chicago, Illinois-based company said it had net ...

AbbVie is poised to grow this year for the first time since Humira's U.S. patent expired. The dividend yields a generous 3.7% and features decades of consistent growth. While tariffs, politics ...

A logo is a big part of any major company's brand identity. It takes a lot of work to create a simple little image that the average consumer can immediately associate with certain features and ...

AbbVie's Rinvoq and Skyrizi could eventually surpass Humira's peak sales. The dividend is well-funded, though an expensive acquisition spree may lead to slower growth. The stock's solid growth ...

Walmart is giving its logo the first facelift in nearly two decades, rolling out a new identity that is a subtle nod to its past. The 61-year-old company unveiled Monday a refresh of its brand ...

If you need financial support to pay for Combigan, or if you need help understanding your insurance coverage, help is available. For example: The Abbvie AYS savings program is available for Combigan.

The price you pay for Combigan may depend on factors such as your dosage, whether you have health insurance, and the pharmacy you use. Financial assistance may be available to help you with the ...

Alvin Chan / SOPA Images / LightRocket via Getty Images Shares of AbbVie plummeted Monday after the company said its schizophrenia drug Emraclidine missed key goals in a pair of trials.

The drug candidate at the center of AbbVie’s $8.7 billion acquisition of Cerevel Therapeutics has failed a pair of phase 2 trials, dealing a blow to the program and a boost to rival Bristol ...

You can reach Elaine on Signal at elaineywchen.70. AbbVie said Monday that its experimental treatment for schizophrenia failed to significantly help patients in two trials, a blow to the company ...